On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during

Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND)

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND)

Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and

Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulat

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing

SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHR

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on a

Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The artic

Omeros (NASDAQ: OMER - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report)

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on

Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquis

JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND)

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on

Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2

Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor

Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty re

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) w

Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on

Arrowstreet Capital Limited Partnership reduced its position in Ligand Pharmaceuticals Incorporated

Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outper

Ashford Capital Management Inc. reduced its position in shares of Ligand Pharmaceuticals Incorporate

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND)

Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy an

Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest na

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor

Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the lates

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that

Acquisition adds seven  commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafeni

Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M f

The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particu

B of A Securities analyst Jason Zemansky maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Bu

Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raise

Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the pro

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention t

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor

Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.50-$9.50 to $8.50-$9.50

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which missed the

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, b

HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) w

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor

Ligand to acquire XOMA Royalty for $739 million, raising 2026 outlook as analysts maintain Buy ratin

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq